The Time Has Come: Surgical Administration of Durable Medical Therapy in Vascular Retinal Diseases

Author(s)/Faculty: Arshad M. Khanani, MD, MA, FASRS; Sara J. Haug, MD, PhD; Dante J. Pieramici, MD; Lejla Vajzovic, MD, FASRS
Release Date: 11/30/2022Expiration Date: 11/29/2023
Credit Type: CMENumber of Credits: 1.25
Content Type: LectureProvider:
Suboptimal outcomes in patients with retinal vascular diseases receiving intravitreal anti-vascular endothelial growth factor (VEGF) therapy have been associated with loss of adherence due to treatment burden. However, novel delivery devices and gene therapies that reduce the need for frequent dosing have now been developed. The Port Delivery System (PDS) with ranibizumab was recently FDA-approved for the management of patients with neovascular age-related macular degeneration (nAMD), while gene therapies are currently being evaluated in ongoing clinical studies. To achieve optimal efficacy and safety outcomes, these novel delivery modalities require unique surgical approaches for their implication into clinical practice. In this CME activity, experts in the field will discuss the risks and benefits of intravitreal versus surgical administration of agents used in the management of patients with retinal vascular diseases, evaluate new and emerging surgically delivered therapies that can enhance outcomes by reducing treatment burden, and provide best practices that can reduce the potential for complications when utilizing the PDS with ranibizumab or subretinal gene therapy in the management of patients with nAMD.